Liver Disease News and Research

RSS

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.

Flu vaccine based upon four strains of inactivated influenza enhances flu protection

A flu vaccine given just under the surface of the skin that includes four strains of inactivated influenza could be more protective than a similar flu vaccine containing only three strains, Saint Louis University research found.

16 Mar 2015

Study describes the dual role of microRNA during hepatitis C infection

In the battle between a cell and a virus, either side may resort to subterfuge. Molecular messages, which control the cellular machinery both sides need, are vulnerable to interception or forgery.

13 Mar 2015

WHO releases first-ever guidance for chronic hepatitis B treatment

WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year - most of them in low- and middle-income countries.

12 Mar 2015

Exposure to hormone-disrupting chemicals can cause fatty liver disease, promote obesity

Exposure to low doses of hormone-disrupting chemicals early in life can alter gene expression in the liver as well as liver function, increasing the susceptibility to obesity and other metabolic diseases in adulthood, a new study finds.

9 Mar 2015

New type of vaccine holds promise for prevention of genital herpes

Scientists at Albert Einstein College of Medicine of Yeshiva University have designed a new type of vaccine that could be the first-ever for preventing genital herpes--one of the most common sexually transmitted diseases, affecting some 500 million people worldwide.

9 Mar 2015

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Astellas today announced that the U.S. Food and Drug Administration has approved its New Drug Application (NDA) for the use of CRESEMBA (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis).

8 Mar 2015

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

40 percent of people in the EU suffer from non-alcoholic steatohepatitis (fatty liver disease), a disease which is becoming increasingly more frequent as a result of diabetes and excess weight in an affluent society. Currently, it is not possible to forecast the further course of the disease - right up to cirrhosis and cancer of the liver. Furthermore, an increased risk of heart attack and kidney damage exists. In future, this should become possible using a Risk Score with different biomarkers.

6 Mar 2015

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

Actavis plc, a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA (levonorgestrel-releasing intrauterine system) by the U.S. Food and Drug Administration for use by women to prevent pregnancy for up to three years.

27 Feb 2015

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

ABIVAX, a clinical stage biotech company developing and commercialising anti-viral compounds and human vaccines, today announced that it has dosed in New Zealand the first patient in a Phase IIb/III clinical trial of ABX203 which is taking place in several countries of the Asia-Pacific region.

26 Feb 2015

Study: Plant compounds can help prevent liver damage during menopause

Women going through menopause often struggle with weight gain that results when their estrogen levels drop, and many turn to weight-loss supplements to help them shed those extra pounds. But those supplements may cause an accumulation of fat in the liver and a potentially life-threatening condition called non-alcoholic fatty liver disease.

26 Feb 2015

Scientists detect new molecule that contributes to development of liver fibrosis

Liver fibrosis, which is the progressive formation of scar tissue in the liver, is a massive medical problem. An estimated ten percent of the population is affected by liver fibrosis or its corresponding later stage, liver cirrhosis. A variety of causes can lead to liver fibrosis, the most widely recognized ones being alcohol consumption and virus-induced chronic liver inflammation.

25 Feb 2015

Betaretrovirus may infect patients with primary biliary cirrhosis

In a new study published in Alimentary Pharmacology & Therapeutics, researchers at the University of Alberta's Faculty of Medicine & Dentistry have shown that a betaretrovirus which resembles a mouse mammary tumor virus infects patients with the rare liver disease, primary biliary cirrhosis (PBC).

20 Feb 2015

Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

Researchers at Albert Einstein College of Medicine of Yeshiva University have found a possible clue to why older mothers face a higher risk for having babies born with conditions such as Down syndrome that are characterized by abnormal chromosome numbers.

19 Feb 2015

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

David Lim, MD, CM, of the University of Alberta has been named the winner of the 2015 Harry M. Vars Award by the American Society for Parenteral and Enteral Nutrition. The award is for his research on parenteral nutrition associated liver disease (PNALD) in infants, which was presented at A.S.P.E.N.'s Clinical Nutrition Week conference in Long Beach, California, February 14 to 17.

19 Feb 2015

Possible cause of liver disease identified in adolescents with cystic fibrosis

A professor at the University of Colorado School of Medicine at the Anschutz Medical Campus and his colleagues have found a possible cause of liver disease in adolescents with cystic fibrosis.

19 Feb 2015

SLU researchers halt fatty liver disease in animal model

Doctors believe that up to 30 percent of the U.S. population may have fat accumulation in the liver, known as non-alcoholic fatty liver disease (NAFLD), that can lead to a range of damaging health consequences.

18 Feb 2015

Harmless plant extract can help treat Cushing Disease

Cushing Disease, not to be confused with Cushing's Syndrome, is caused by a tumour in the pituitary gland in the brain. The tumour secrets increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness.

16 Feb 2015

Increasing opioid doses to manage chronic pain may intensify depression

Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to Saint Louis University findings in Pain.

16 Feb 2015

Researchers develop novel approach to identify potential antimalarial drugs

Each year nearly 600,000 people--mostly children under age five and pregnant women in sub-Saharan Africa--die from malaria, caused by single-celled parasites that grow inside red blood cells. The most deadly malarial species--Plasmodium falciparum--has proven notoriously resistant to treatment efforts.

12 Feb 2015

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced top-line results from the 4 mg/kg cohort and additional results from the 2 mg/kg cohort in a completed clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122 ("miR-122"), for the treatment of hepatitis C virus infection ("HCV").

9 Feb 2015

Liver Disease News and Research

Further Reading

Flu vaccine based upon four strains of inactivated influenza enhances flu protection

Study describes the dual role of microRNA during hepatitis C infection

WHO releases first-ever guidance for chronic hepatitis B treatment

Exposure to hormone-disrupting chemicals can cause fatty liver disease, promote obesity

New type of vaccine holds promise for prevention of genital herpes

FDA approves Astellas' CRESEMBA for treatment of invasive aspergillosis, invasive mucormycosis

Biomarker for compilation of Risk Score for non-alcoholic steatohepatitis

FDA approves LILETTA (levonorgestrel-releasing intrauterine system) to prevent pregnancy

ABIVAX doses first patient in ABX203 Phase IIb/III trial for treatment of chronic hepatitis B

Study: Plant compounds can help prevent liver damage during menopause

Scientists detect new molecule that contributes to development of liver fibrosis

Betaretrovirus may infect patients with primary biliary cirrhosis

Einstein researchers find possible clue to why older mothers have babies born with Down syndrome

University of Alberta researcher named winner of A.S.P.E.N.'s 2015 Harry M. Vars Award

Possible cause of liver disease identified in adolescents with cystic fibrosis

SLU researchers halt fatty liver disease in animal model

Harmless plant extract can help treat Cushing Disease

Increasing opioid doses to manage chronic pain may intensify depression

Researchers develop novel approach to identify potential antimalarial drugs

Regulus Therapeutics reports top-line results from RG-101 clinical study for HCV treatment

Pioneering Live Cell Imaging - Yokogawa's Impact and Innovations

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Latest News